Clémence Toullec

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability

Olivier Bouché, Thierry André, Karine Le Malicot et al. · JAMA Oncology · 2023 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial

Thierry André, Farid El Hajbi, Emilie Barbier et al. · Digestive and Liver Disease · 2020 · 26 citations

Medicine, Oncology, Chemotherapy +13

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jérôme Fayette, Lisa Licitra, Kevin J. Harrington et al. · Clinical Cancer Research · 2025 · 19 citations · Full text

Medicine, Oncology, Pharmacology +16

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME

Thomas Chevalier, Amaury Daste, Esmaa Saada‐Bouzid et al. · Cancer Medicine · 2021 · 17 citations · Full text

Medicine, Oncology, Pharmacology +15